Voloridge Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Voloridge Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-179,285	Closed	-$19.2M	–	1627
2023 Q1	$19.2M	Sell	179,285 -67,963	-27%	-$7.82M	0.1%	292
2022 Q4	$27.2M	Buy	247,248 +43,128	+21%	+$2.8M	0.15%	197
2022 Q3	$12M	Buy	204,120 +37,863	+23%	+$1.73M	0.07%	393
2022 Q2	$4.69M	Buy	166,257 +58,561	+54%	+$1.7M	0.02%	703
2022 Q1	$4.07M	Buy	+107,696	New	+$4.26M	0.02%	706

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Voloridge Investment Management's RXDX Position: Q2 2023 in Review

Voloridge Investment Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 179,285 shares — an estimated $19.2M sold.

Voloridge Investment Management first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $27.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Voloridge Investment Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Voloridge Investment Management sold 179,285 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $19.2M.
Voloridge Investment Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Voloridge Investment Management's Prometheus Biosciences, Inc. Common Stock position peaked at $27.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Voloridge Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.